{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:41Z","timestamp":1790222861776,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2889-4","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T07:04:00Z","timestamp":1513753440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rapid and large-scale implementation of HCV treatment advances in France, 2007\u20132015"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7400","authenticated-orcid":false,"given":"C\u00e9cile","family":"Brouard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Boussac-Zarebska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de L\u00e9dinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"Pillonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Delarocque-Astagneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"2889_CR1","unstructured":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology. 2017;2:161\u201376."},{"key":"2889_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"2889_CR3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained Virological response. Clin Infect Dis. 2015;61:730\u201340.","journal-title":"Clin Infect Dis"},{"key":"2889_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","volume":"15","author":"J Smith-Palmer","year":"2015","unstructured":"Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.","journal-title":"BMC Infect Dis"},{"key":"2889_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"2889_CR6","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417\u201328.","journal-title":"N Engl J Med"},{"key":"2889_CR7","doi-asserted-by":"crossref","unstructured":"Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195\u2013206.","DOI":"10.1056\/NEJMoa1010494"},{"key":"2889_CR8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199\u2013236.","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"2889_CR9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL recommendations on Treatment of Hepatitis C 2014. J Hepatol. 2014;61:373\u201395.","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"2889_CR10","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13:e1002032.","journal-title":"PLoS Med"},{"key":"2889_CR11","first-page":"310","volume":"4","author":"SM Lynch","year":"2016","unstructured":"Lynch SM, Hepatitis WGY, Virus C, Review A. Of treatment guidelines, cost-effectiveness, and access to therapy. Journal of clinical and translational hepatology. 2016;4:310\u20139.","journal-title":"Journal of clinical and translational hepatology"},{"key":"2889_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5582\/irdr.2016.01054","volume":"5","author":"G Balasubramanian","year":"2016","unstructured":"Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of compassionate use programs in the European Union member states. Intractable & Rare Diseases Research. 2016;5:244\u201354.","journal-title":"Intractable & Rare Diseases Research"},{"key":"2889_CR13","unstructured":"Minist\u00e8re des Affaires sociales et de la Sant\u00e9. Discours de Marisol Touraine - Journ\u00e9e de lutte contre les h\u00e9patites virales. http:\/\/social-sante.gouv.fr\/actualites\/presse\/discours\/article\/discours-de-marisol-touraine-journee-de-lutte-contre-les-hepatites-virales . Accessed 3 Apr 2017."},{"key":"2889_CR14","unstructured":"Haute autorit\u00e9 de sant\u00e9. Prise en charge de l'h\u00e9patite C par les m\u00e9dicaments anti-viraux \u00e0 action directe (AAD). Elargissement du p\u00e9rim\u00e8tre de remboursement. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2016-12\/recommandation_college_hepatite_c.pdf . Accessed 2 Feb 2017."},{"key":"2889_CR15","unstructured":"Haute autorit\u00e9 de sant\u00e9. Prise en charge de l'h\u00e9patite C par les m\u00e9dicaments anti-viraux \u00e0 action directe (AAD). http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2014-07\/hepatite_c_prise_en_charge_anti_viraux_aad.pdf . Accessed 10 Apr 2017."},{"key":"2889_CR16","unstructured":"Prise en charge des personnes infect\u00e9es par les virus de l'h\u00e9patite B ou de l'h\u00e9patite C. Rapport de recommandations 2014. Sous la direction du Professeur Daniel Dhumeaux et sous l'\u00e9gide de l'ANRS et de l'AFEF. http:\/\/social-sante.gouv.fr\/IMG\/pdf\/Rapport_Prise_en_charge_Hepatites_2014.pdf . Accessed 12 Mar 2017."},{"key":"2889_CR17","volume-title":"Mod\u00e9lisation de l'impact \u00e9pid\u00e9miologique des nouveaux anti-viraux dans le traitement de l'h\u00e9patite C","author":"H Leleu","year":"2013","unstructured":"Leleu H, Razavi H, H\u00e9zode C, Blachier M, Roudot-Thoraval F. Mod\u00e9lisation de l'impact \u00e9pid\u00e9miologique des nouveaux anti-viraux dans le traitement de l'h\u00e9patite C. Lille: 73\u00e8mes Journ\u00e9es de l'Association Fran\u00e7aise pour l'Etude du Foie (AFEF); 2013."},{"key":"2889_CR18","first-page":"224","volume":"13\u201314","author":"C Pioche","year":"2016","unstructured":"Pioche C, Pelat C, Larsen C, Desenclos JC, Jauffret Roustide M, Lot F, et al. Estimation de la pr\u00e9valence de l'h\u00e9patite C en population g\u00e9n\u00e9rale, France m\u00e9tropolitaine, 2011. Bull Epidemiol Hebd. 2016;13\u201314:224\u20139.","journal-title":"Bull Epidemiol Hebd"},{"key":"2889_CR19","doi-asserted-by":"crossref","first-page":"e0126920","DOI":"10.1371\/journal.pone.0126920","volume":"10","author":"C Brouard","year":"2015","unstructured":"Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One. 2015;10:e0126920.","journal-title":"PLoS One"},{"key":"2889_CR20","first-page":"230","volume":"13\u201314","author":"MD Pauti","year":"2016","unstructured":"Pauti MD, Tomasino A, Mari C, Mathieu C, Kartner A, Idrissu C, et al. Limiter les opportunit\u00e9s manqu\u00e9es de d\u00e9pistage des h\u00e9patites B et C chez les migrants en situation de pr\u00e9carit\u00e9 : le programme de M\u00e9decins du Monde en France. Bull Epidemiol Hebd. 2016;13\u201314:230\u20136.","journal-title":"Bull Epidemiol Hebd"},{"key":"2889_CR21","doi-asserted-by":"crossref","unstructured":"Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18.","DOI":"10.2807\/1560-7917.ES2013.18.28.20524"},{"key":"2889_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.respe.2015.10.003","volume":"64","author":"L Weill-Barillet","year":"2016","unstructured":"Weill-Barillet L, Pillonel J, Semaille C, Leon L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64:301\u201312.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2889_CR23","doi-asserted-by":"crossref","unstructured":"Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2016:1\u201313.","DOI":"10.1017\/S0950268816002934"},{"key":"2889_CR24","unstructured":"Sant\u00e9 publique France. Surveillance nationale de l'h\u00e9patite C \u00e0 partir des p\u00f4les de r\u00e9f\u00e9rence volontaires. R\u00e9partition des g\u00e9notypes chez les patients vir\u00e9miques. http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Hepatites-virales\/Hepatite-C\/Surveillance-nationale-de-l-hepatite-C-a-partir-des-poles-de-reference-volontaires\/Donnees-epidemiologiques-2001-2007 . Accessed 10 Apr 2017."},{"key":"2889_CR25","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/liv.12388","volume":"34","author":"G Geri","year":"2014","unstructured":"Geri G, Maynard M, Rosenthal E, Fontaine H, Lacombe K, Slama L, et al. Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. Liver Int. 2014;34:1349\u201357.","journal-title":"Liver Int"},{"key":"2889_CR26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","volume":"36","author":"G Moulis","year":"2015","unstructured":"Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36:411\u20137.","journal-title":"Rev Med Interne"},{"key":"2889_CR27","doi-asserted-by":"crossref","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017.","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"2889_CR28","unstructured":"Haute autorit\u00e9 de sant\u00e9. Actes et prestations. Affection de longue dur\u00e9e. H\u00e9patite chronique C. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/lap_ald_6_vhc__actualisation_dec_2007_.pdf . Accessed 10 Apr 2017."},{"key":"2889_CR29","doi-asserted-by":"crossref","unstructured":"European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32(Suppl 1):2-8.","DOI":"10.1111\/j.1478-3231.2011.02703.x"},{"key":"2889_CR30","doi-asserted-by":"crossref","unstructured":"Hezode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017.","DOI":"10.1111\/liv.13383"},{"key":"2889_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","volume":"66","author":"S Pol","year":"2017","unstructured":"Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66:39\u201347.","journal-title":"J Hepatol"},{"key":"2889_CR32","unstructured":"Association Fran\u00e7aise pour l'Etude du Foie (AFEF). AFEF guidelines. Management of hepatitis C virus infection. http:\/\/www.afef.asso.fr\/ckfinder\/userfiles\/files\/actualites\/veille\/French-HCV-guidelines-June-2015.pdf . Accessed 29 Mar 2017."},{"key":"2889_CR33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C Hezode","year":"2013","unstructured":"Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434\u201341.","journal-title":"J Hepatol"},{"key":"2889_CR34","doi-asserted-by":"publisher","unstructured":"Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015. J Hepatol. 2017;67:15-22. doi: 10.1016\/j.jhep.2017.01.024 .","DOI":"10.1016\/j.jhep.2017.01.024"},{"key":"2889_CR35","unstructured":"Dessauce C, Rudant J, Expert A, Barth\u00e9lemy P, Cadier B. Les antiviraux \u00e0 action directe (AAD) dans le traitement de l'h\u00e9patite C: retour sur 18 mois de prise en charge par l'Assurance Maladie. Points de rep\u00e8re. 2016;44:1-7. https:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/Points_de_repere_n_44_-_Antiviraux_a_action_directe_et_hepatite_C_-_corrige.pdf.pdf ."},{"key":"2889_CR36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/jmv.21734","volume":"82","author":"C Meffre","year":"2010","unstructured":"Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82:546\u201355.","journal-title":"J Med Virol"},{"key":"2889_CR37","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciw567","volume":"63","author":"P Ingiliz","year":"2016","unstructured":"Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-Monoinfected and HIV-HCV-Coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63:1320\u20134.","journal-title":"Clin Infect Dis"},{"key":"2889_CR38","doi-asserted-by":"publisher","unstructured":"Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. J Gastroenterol Hepatol. 2017;32:1136-42. doi: 10.1111\/jgh.13652 .","DOI":"10.1111\/jgh.13652"},{"key":"2889_CR39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14737167.2016.1247696","volume":"16","author":"AL Mouterde","year":"2016","unstructured":"Mouterde AL, Bocquet F, Fusier I, Paubel P, Hepatitis C. How has France limited the expenses related to new treatments? Expert Rev Pharmacoecon Outcomes Res. 2016;16:655\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2889_CR40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2893.2009.01196.x","volume":"17","author":"E Delarocque-Astagneau","year":"2010","unstructured":"Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat. 2010;17:435\u201343.","journal-title":"J Viral Hepat"},{"key":"2889_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.respe.2015.12.015","volume":"64","author":"P Tuppin","year":"2016","unstructured":"Tuppin P, Samson S, Colinot N, Gastaldi-Menager C, Fagot-Campagna A, Gissot C. Health care use by free complementary health insurance coverage beneficiaries in France in 2012. Rev Epidemiol Sante Publique. 2016;64:67\u201378.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2889_CR42","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhep.2016.10.006","volume":"66","author":"S Deuffic-Burban","year":"2017","unstructured":"Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? J Hepatol. 2017;66:304\u201312.","journal-title":"J Hepatol"},{"key":"2889_CR43","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.27403","volume":"60","author":"M Hellard","year":"2014","unstructured":"Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60:1861\u201370.","journal-title":"Hepatology"},{"key":"2889_CR44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","volume":"22","author":"NK Martin","year":"2015","unstructured":"Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015;22:399\u2013408.","journal-title":"J Viral Hepat"},{"key":"2889_CR45","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1 . Accessed 12 Mar 2017."},{"key":"2889_CR46","unstructured":"Prise en charge th\u00e9rapeutique et suivi de l'ensemble des personnes infect\u00e9es par le virus de l'h\u00e9patite C. Rapport de recommandations 2016. Sous la direction du Pr Daniel Dhumeaux. Sous l'\u00e9gide de l'ANRS et du CNS et avec le concours de l'AFEF. http:\/\/social-sante.gouv.fr\/IMG\/pdf\/rapport_.pdf . Accessed 10 Feb 2017."},{"key":"2889_CR47","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/liv.13135","volume":"36","author":"J Bottero","year":"2016","unstructured":"Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int. 2016;36:1442\u20139.","journal-title":"Liver Int"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2889-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T05:14:32Z","timestamp":1570511672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2889-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2889"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2889-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"784"}}